ArticleFrontiers in pharmacology2010
Policies to enhance prescribing efficiency in europe: findings and future implications.
Article in Frontiers in pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Promoting Sustainable Prescribing-A Case Study Presenting Experiences From Two Swedish Drug and Therapeutics Committees.Pharmacology research & perspectives · 2026Article
- Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution.Healthcare (Basel, Switzerland) · 2022Review
- The Current Situation Regarding Long-Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future.Frontiers in public health · 2021Article
- Sources of Information on Medicinal Products Among Physicians - A Survey Conducted Among Primary Care Physicians in Poland.Frontiers in pharmacology · 2021Article
- Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.BioMed research international · 2021Article
- Article
- Consumption of medicines used for gastric acid-related disorders in Australia and South Korea: a cross-country comparison.European journal of clinical pharmacology · 2020Article
- Statin prescription among patients with type 2 diabetes in Botswana: findings and implications.BMC endocrine disorders · 2020Article
- Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.Frontiers in pharmacology · 2020Article
- The Expiry of HumiraFrontiers in pharmacology · 2020Article
- Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future.Frontiers in pharmacology · 2020Review
- Effect of reimbursement restriction policy on the use of benzodiazepines in the Netherlands: an interrupted time series analysis.BMJ open · 2019Article
- Patterns of statin utilisation for new users and market dynamics in South Korea: a 13-year retrospective cohort study.BMJ open · 2019Article
- Utilization and Expenditure of Anti-cancer Medicines in Kosovo: Findings and Implications.PharmacoEconomics - open · 2018Article
- Policies for biosimilar uptake in Europe: An overview.PloS one · 2017Article
- Pattern of statin use changes following media coverage of its side effects.Patient preference and adherence · 2017Article
- Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.Frontiers in pharmacology · 2017Review
- Rational use of medicines: Cost consideration & way forward.The Indian journal of medical research · 2016Article
- Time trends in statin utilisation and coronary mortality in Western European countries.BMJ open · 2016Article
- Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.Frontiers in pharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEuropean countries need to learn from each other to address unsustainable increases in pharmaceutical expenditures.
objectiveTo assess the influence of the many supply and demand-side initiatives introduced across Europe to enhance prescribing efficiency in ambulatory care. As a result provide future guidance to countries.
methodsCross national retrospective observational study of utilization (DDDs - defined daily doses) and expenditure (Euros and local currency) of proton pump inhibitors (PPIs) and statins among 19 European countries and regions principally from 2001 to 2007. Demand-side measures categorized under the "4Es" - education engineering, economics, and enforcement.
resultsInstigating supply side initiatives to lower the price of generics combined with demand-side measures to enhance their prescribing is important to maximize prescribing efficiency. Just addressing one component will limit potential efficiency gains. The influence of demand-side reforms appears additive, with multiple initiatives typically having a greater influence on increasing prescribing efficiency than single measures apart from potentially "enforcement." There are also appreciable differences in expenditure (€/1000 inhabitants/year) between countries. Countries that have not introduced multiple demand side measures to counteract commercial pressures to enhance the prescribing of generics have seen considerably higher expenditures than those that have instigated a range of measures.
conclusionsThere are considerable opportunities for European countries to enhance their prescribing efficiency, with countries already learning from each other. The 4E methodology allows European countries to concisely capture the range of current demand-side measures and plan for the future knowing that initiatives can be additive to further enhance their prescribing efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.